{"analyses":[{"ciLowerLimit":"1.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.0","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Odds Ratio (OR)","paramValue":"2.5","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.8","upperLimit":"74.8","value":"68.1"},{"groupId":"OG001","lowerLimit":"41.1","upperLimit":"56.1","value":"48.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"181"}],"units":"Participants"}],"description":"Percentage of participants who are RBC transfusion-free over a consecutive 84-day period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"NUMBER","populationDescription":"ITT Population - all randomized participants regardless of whether or not the participant received treatment.","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 24","title":"Percentage of Participants Achieving Red Blood Cell Transfusion Independence (RBC-TI) for ≥ 12 Weeks (84 Days)","type":"SECONDARY","unitOfMeasure":"Percent of participants"}